Caris Life Sciences, Inc.’s Lock-Up Period To End on December 15th (NASDAQ:CAI)

Caris Life Sciences’ (NASDAQ:CAI) lock-up period is set to end on Monday, December 15th. Caris Life Sciences had issued 23,529,412 shares in its IPO on June 18th. The total size of the offering was $494,117,652 based on an initial share price of $21.00. After the expiration of the company’s lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on CAI shares. Weiss Ratings assumed coverage on shares of Caris Life Sciences in a report on Thursday. They issued a “sell (d)” rating for the company. Canaccord Genuity Group upgraded shares of Caris Life Sciences to a “hold” rating in a research note on Tuesday, December 2nd. Finally, Wall Street Zen downgraded Caris Life Sciences from a “buy” rating to a “hold” rating in a research report on Saturday. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

Caris Life Sciences Price Performance

Shares of NASDAQ CAI opened at $28.86 on Monday.

Caris Life Sciences Company Profile

We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.